A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing

The Readout LOUD A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing Manage alerts for this article Email this article Share this article By Allison DeAngelis and Elaine ChenJuly 23, 2026 Allison DeAngelis[email protected]Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01.Elaine Chen[email protected]Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. What does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that’s partnered with Novo Nordisk? And has a wanted fugitive been posing as a biotech executive? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We speak with our colleagues Jason Mast and Matthew Herper about their impactful look at one father’s mission to develop a treatment for his daughter’s ultra-rare disease. The subject of that feature, Matt Wilsey, also joins us.Advertisement We also discuss STAT’s investigation into the GLP-1 prescribing practices of telehealth company LifeMD, as well as other news in the life sciences, including a legal battle between Novo Nordisk and Eli Lilly and the latest revelations on a most-wanted fugitive. To read the feature on Wilsey, go here; for more on the investigation into the telehealth company, go here; to learn more about the fugitive, go here; and for more on Novo and Lilly’s legal battle, go here. Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.Advertisement biotechnology, drug development, Eli Lilly, Novo Nordisk, rare diseases Submit a correction requestReprints Allison DeAngelis Biotech Startups and Venture Capital Reporter Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01. Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended The Readout LOUD July 16, 2026 Predicting biotech clinical trials and a new Alzheimer’s drug controversy The Readout LOUD July 9, 2026 Whistleblower takes on health insurance and FDA commissioner candidates Advertisement The Readout LOUD June 25, 2026 The mysterious case of Eli Lilly’s obesity drug The Readout LOUD June 18, 2026 New hope in treating Huntington’s disease and a report card on RFK Jr.’s promises The Readout LOUD June 11, 2026 STAT Plus: An obesity drug deep-dive, and peptides move mainstream Subscriber Picks